Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner 

Axsome Therapeutics said the FDA wants safety information from the biotech’s third Phase III study of its drug candidate for Alzheimer’s disease agitation before submitting a label expansion request.